Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Guangzhou 15 Shanghai 10 Hefei 7 Bengbu 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing18 Guangzhou15 Shanghai10 Hefei7 Bengbu6
All 39 locations
Target enrolment
to

Trials with a site in Guangzhou

15 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
NCT07892274Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
226
Guangzhou
2026-11-01
Recruiting
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-08-10
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou
2026-05-21
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
596
Guangzhou, Chengdu
2026-04-21
Recruiting
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
NCT06892093HER2-positive Breast Cancer, Diarrhea Caused by Drug, Neratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
308
Guangzhou
2025-08-07
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
NCT07358182Trastuzumab-rezetecan, HER2-low Breast Cancer, HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2025-06-01
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

9 of the 15 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 15 studies
PhaseStudiesRecruitingShare
Phase 38353.3%
Observational2213.3%
Phase 22113.3%
Phase 2/32213.3%
Not applicable116.7%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.42
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University43
Seagen, a wholly owned subsidiary of Pfizer20
Chengdu SciMount Pharmatech Co., Ltd.11
Daiichi Sankyo11
DualityBio Inc.10
GeneQuantum Healthcare (Suzhou) Co., Ltd.11
Hoffmann-La Roche11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.